Despite its silent growth, typhoid poses a mounting health challenge in India, exacerbated by diagnostic limitations and increasing antibiotic resistance, prompting calls for broader vaccination and improved surveillance efforts.
Typhoid is drawing less public attention than influenza or swine flu, yet the disease is quietly becoming a bigger concern in India. As the Indian Express opinion column notes, that matters not only because typhoid remains widespread, but because each suspected case can lead to unnecessary or overly broad antibiotic use, adding to the country’s antimicrobial-resistance problem.
The central difficulty is diagnosis. The column argues that typhoid is vaccine-preventable but still often treated on suspicion rather than proof, because there is no simple, dependable and widely available test. A single Widal result is not enough to confirm acute typhoid, especially in a country where prior exposure, background antibodies and vaccination can distort interpretation. Blood culture is the laboratory standard, but the World Health Organisation says a single culture detects only about 55% to 60% of cases, and results are further weakened if a patient has already taken antibiotics. That leaves clinicians stuck between uncertainty and pressure to prescribe.
Recent research suggests the scale of the problem is substantial. A 2023 burden study published in a peer-reviewed journal estimated about 4.9 million typhoid cases and 7,850 deaths in India, with a large share of hospitalisations linked to fluoroquinolone-resistant strains. The London School of Hygiene & Tropical Medicine said the findings show typhoid is still affecting millions and that drug resistance is making treatment harder, especially for young children. Another modelling study also urged India to include typhoid conjugate vaccines in the Universal Immunisation Programme.
The policy answer, the column says, is not antibiotics alone but a broader control strategy. That means stronger surveillance, better laboratory practice, collecting blood cultures before treatment starts, and investment in a rapid point-of-care test. It also means treating vaccination as a core public-health tool rather than an optional extra. India already has home-grown typhoid conjugate vaccine capacity, including WHO-prequalified products, so the challenge is less scientific than practical: scaling use, improving prevention and reducing avoidable antibiotic pressure before resistance worsens further.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
